Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-812 (Qelbree) Long-Term Safety and Efficacy in Adult ADHD
NCT04143217Phase 3Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jan 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of viloxazine in attention deficit hyperactivity disorder (ADHD), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Incidence of Adverse Events up to 156 weeks. Started Jan 2020; status: completed.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04143217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143217.